Autopsy report · NCT05041972

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

“Business strategy change”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Ambrx, Inc.

Sponsor type

Industry

Conditions

HER2 Mutation-Related Tumors; HER2 Amplified Solid Tumors

Interventions

ARX788

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (97% match in meaning)
• A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
  “Business strategy” (85% match in meaning)
• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
  “Strategy Change” (84% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (83% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.